Infections caused by MDR A. baumannii have high mortality rates, associated with antimicrobial resistance and the limited treatment options [2] . Polymyxin B (PMB) and polymyxin E (Colistin) are often the drugs of last resort to treat these infections, although isolates resistant to these antimicrobial agents have emerged [3] . For this reason, the use of antimicrobial combinations is recommended especially for MDR strains [4] . Therapies using antimicrobial combinations, including polymyxins, have shown promising results as they disrupt the outer membrane of GN bacilli, facilitating the penetration of other antimicrobials into the cell [5] . Vancomycin (VAN) is indicated for infections caused by Gram-positive bacteria, and acts by forming a complex with the C-terminal d-alanine residues present in peptidoglycan precursors, interrupting cell wall synthesis. Because of its large size and complex structure, VAN does not penetrate the outer membrane of GN bacteria [6] , but the membrane-disrupting properties of polymyxins could allow VAN to reach its periplasmic target and act against GN bacteria [7] .
Some studies have evaluated the COL-VAN antimicrobial combination against MDR A. baumannii. However, to the best of our knowledge, no studies evaluating the antimicrobial activity of the PMB-VAN combination against MDR A. baumannii isolates have yet been conducted. This study assessed the in vitro efficacy of PMB plus VAN against OXA-23-producing PMB-resistant and PMB-sensitive isolates of A. baumannii with different clonal origins.
MeTHOdS

Bacterial samples
In two university hospitals in southern Brazil, 472 isolates of A. baumannii were collected consecutively from intensive care units. According to the breakpoints established by the Clinical and Laboratory Standards Institute (CLSI) [9] , we included six isolates, all carbapenem-resistant A. baumannii (MIC ≥4 µg ml -1 ), three PMB-resistant (MIC ≥4 µg ml -1 ) and three PMB-susceptible (MIC ≤2 µg ml -1 ) ( Table 1 ). All isolates contained the genes bla OXA-51 and bla , as confirmed by the PCR test. The six isolates were classified into six different clusters with different clonal origins, based on the enterobacterial repetitive intergenic consensus-PCR (ERIC-PCR) [10] . The pathogens were identified using a Phoenix BD Automated Microbiology System (Becton Dickinson and Co., Sparks, MD, USA) and were obtained from clinical specimens: four isolates from tracheal aspirates and two from catheter tips. The susceptibility of the isolates to PMB was determined by the Etest, broth microdilution and agar dilution assays and reference strains (Escherichia coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853) were used in all assays according to the CLSI. VAN MICs against each isolate were determined using the broth microdilution method as described in the CLSI M07-A10, Approved Standard [11] . Reference strains (Staphylococcus aureus ATCC 29313 and Enterococcus faecalis ATCCC 29212) were used in all assays according to the CLSI.
Synergy studies
The in vitro activity of the PMB-VAN combination was evaluated using four different methods (checkerboard, time-kill, disk-diffusion and M.I.C.Evaluator) as described below.
Checkerboard assay
PMB and VAN alone and in combination were evaluated by the checkerboard assay in 96-well microtitre plates (Inlab, São Paulo, Brazil). Briefly, the inoculum of each bacterial isolate was prepared in cation-adjusted Mueller-Hinton broth (CA-MHB) at a 0.5 McFarland standard and added to the wells with a final concentration of 5×10 5 c.f.u. ml -1 . The test was conducted in duplicate, and in cases of discordant values, the experiment was repeated. After incubation at 37 °C for 16 to 20 h, the MICs for the antibiotics alone and in combination were determined for each individual isolate. The activity of the drug combination was classified according to the fractional inhibitory concentration index (FICI), which was calculated by adding the MIC of each individual drug when used in combination, divided by the MIC of the drug used alone. The effect of the antimicrobial combination therapy was classified according to the following categories: synergism FICI ≤0.5; indifference 0.5<FICI<4 and antagonism FICI ≥4 [12] .
Time-kill assay
In the time-kill assay, tubes containing PMB and VAN alone and in combination (0.5×MIC) were inoculated with 10 6 c.f.u. ml -1 of each isolate and incubated with continuous shaking at 37 °C. Samples were collected at 0, 6, 12 and 24 h, serially diluted in saline, plated on Mueller-Hinton Agar (MHA), and counted after 24 h of incubation. Time-kill curves were constructed by plotting mean colony counts (log 10 c.f.u. ml -1 ) versus time. The drug combination was considered synergistic when a reduction in colony count of 2 log 10 was reached after 24 h (bacteriostatic activity ≥2 log 10 and <3 log 10 ; and bactericidal activity ≥3 log 10 ) in comparison with the higher concentration of a single agent. The drug combination was classified as indifferent when an increase or decrease of <2 log 10 in colony counts was observed, and it was considered antagonistic when an increase of >2 log 10 in colony counts was reached after 24 h, in comparison with the more active single agent [13] .
disk-diffusion and M.I.C.evaluator assays
Disk-diffusion and antimicrobial gradient strip (Oxoid M.I.C.Evaluator) assays were based on a previously described method [7] . Briefly, plates were inoculated in three directions with inoculum equivalent to a 0.5 McFarland turbidity standard, a VAN disk (Oxoid; 30 µg) and a VAN-gradient strip were applied on the surface of agar plates with PMB (0.5×MIC) and incubated at 37 °C for 18-20 h. VAN MICs in the presence of PMB were compared to VAN MICs in the absence of PMB. If the VAN MIC was reduced within a onefold dilution, the result was interpreted as indifferent; if it was reduced by a one to twofold dilution, the result was considered additive; if it was reduced by a >threefold dilution, the result was considered synergistic [14] . The synergistic effect in the disk-diffusion was defined when the inhibition zone of the VAN disk in the presence of PMB increased at least 5 mm in relation to the inhibition zone of the VAN disk without PMB [15] .
Additional PMB-resistance analyses
Mcr-1 gene amplification
The mcr-1 gene was detected using the PCR method. Bacterial DNA was extracted with the boiling method. The primers in this study (forward primer, 5′-CGGTCAGTCCGTTT-GTTC-3′, and reverse primer, 5′-CTTGGTCGGTCTG-TAGGG-3′) were previously described by Liu et al. [16] and used at a concentration of 10 pmol µl -1 in the PCR mixture. The following cycling parameters were employed for amplification: initial DNA denaturation at 95 °C for 5 min, 30 cycles at 95 °C for 1 min, annealing at 56 °C for 45 s and extension at 72 °C for 1 min, followed by a single elongation step at 72 °C for 5 min. Amplified products were analysed on gel containing 1.5 % agarose, stained with ethidium bromide. After running for 50 min at constant voltage (100 V), the gel FICI, fractional inhibitory concentration index;MIC, minimum inhibitory concentration;PMB, polymyxin B; VAN, vancomycin. was observed and photographed with an ultraviolet transilluminator l-PIX HE (Loccus Biotecnologia, São Paulo, Brazil) under ultraviolet light.
Mutant frequency
Mutant frequency (MF) was determined as previously described by Zhanel et al. [17] , with some modifications. The bacterial concentration of 10 10 c.f.u. ml -1 of the samples was quantified by serial dilutions and 20 µl of each dilution was plated on MHA-plates with and without the antimicrobials, in triplicate, in order to count mutant colonies. PMB concentrations tested ranged from 1 to 8 times the PMB MIC of each isolate. The MFs for PMB were calculated by multiplying the number of mutant colonies by 50 to convert to c.f.u. ml -1 , and the result was divided by the initial bacterial inoculum.
ReSUlTS ANd dISCUSSION
Infections caused by MDR A. baumannii, similarly to those resistant to carbapenems, are difficult to treat. Identification of synergism between antimicrobials is important because of the few treatment options available [14] . Although several studies have demonstrated the synergistic effect of the COL-VAN combination against A. baumannii [7, 18, 19] , our data add significant information, demonstrating PMB-VAN synergism in 50% of the isolates tested, regardless of the method used ( Table 1) .
The results of the checkerboard and time-kill assays agreed in four/six of the isolates (67%), indicating a lack of direct correlation between tests. This result was expected, since these techniques measure different parameters, and should be used together and not comparatively in detecting synergism [20] .
In the checkerboard assay (Fig. 1c) , PMB plus VAN showed synergism (FICI ≤0.5) against three PMB-resistant isolates, with two of them changing categories from resistant to susceptible to PMB. In a study of three COL-resistant isolates, O'Hara et al. [19] observed a synergistic effect of the COL-VAN combination for all isolates, similarly to the present study. As shown for the COL-VAN combination by other authors [21] [22] [23] , we also found that the PMB-VAN combination showed high rates of synergism in polymyxin-resistant isolates in relation to polymyxin-susceptible isolates (Table 1) . A possible explanation for this is that lipopolysaccharides (LPS) contain binding sites for VAN, which prevents the entrance of VAN into Gram-negative bacteria [24] , and one of the mechanisms of resistance to polymyxins in A. baumannii may be either by complete loss of LPS or by alteration of lipid A [25] . Thus, in polymyxin-resistant isolates, a decrease in VAN-resistance can be observed [26] .
In the PMB-VAN combination, none of the isolates showed an antagonistic effect with checkerboard testing. This combination also showed a reduction in the MICs of both antibiotics against four isolates, and increased bacterial susceptibility to at least one of the antimicrobials tested in combination for two isolates. The reductions in PMB MICs ranged from one to fivefold for all isolates. Although VAN showed no antimicrobial activity against A. baumannii isolates, when combined with PMB, a four to sevenfold decrease in the MICs occurred in four/six of the isolates (67%). The reductions in MICs of antimicrobials and changes in the susceptibility category against the isolates tested were not found in other studies [7, 19, 22] .
The time-kill assay indicated a synergistic effect of the PMB-VAN combination in two PMB-resistant isolates (Ac-680 and Ac-Cl) and one PMB-susceptible isolate (Ac-68). For these isolates, the PMB-VAN combination showed a bacteriostatic effect after 6 h, and a bactericidal effect after 24 h (Fig. 2) . In relation to isolates that showed indifference (Ac-576, Ac-53 and Ac-S22), despite the ≥3 log 10 c.f.u. ml -1 decrease after 6 h, regrowth occurred between 12 and 24 h. In contrast, Yang et al. [18] observed that when the COL-VAN combination was tested against four A. baumannii isolates, two COL-susceptible isolates showed a bactericidal effect, with no regrowth. Although the two COL-resistant isolates initially also showed bactericidal activity, regrowth was observed at 24 h.
The present study also evaluated the synergy using the VAN-gradient strip and a VAN disk in a medium containing PMB (Fig. 1) . The disk-diffusion test showed synergism in all PMB-resistant isolates, while the antimicrobial-gradient strip indicated a significant decrease in MIC values. For all PMB-susceptible isolates, no significant differences between ), Ac-53, Ac-68 and Ac-S22 (polymyxin B -0.25 µg ml -1 ). For all isolates a vancomycin concentration of 128 µg ml -1 was used.
the tests were observed with or without PMB on the MHA plates. Gordon et al. [7] performed synergy testing of the COL-VAN combination with the Etest method against 40 isolates of MDR A. baumannii susceptible to COL. Initial VAN MICs were >256 µg ml -1 and when the VAN Etest was combined with 0.5 µg ml -1 of COL supplemented on agar, VAN MICs were reduced in all cases, ranging from 0.016 to 48 µg ml -1 . Differently from the study conducted by Gordon et al. [7] , we used PMB-resistant isolates, PMB instead of COL, and we added a new in vitro synergy test with a VAN disk (Fig. 1) . Based on these results, we believe that the disk-diffusion and antimicrobial-gradient strip tests may be reliable methods to evaluate the synergistic effect of the PMB-VAN combination in the laboratory, as both showed similar synergism results to the checkerboard test.
The PCR demonstrated that all PMB-resistant isolates were negative for the mcr-1 gene. However, caution must be exercised as other mechanisms involved in polymyxin resistance have not been investigated. The mutant frequency investigation showed interesting results. Two isolates (Ac-680 and Ac-Cl) demonstrated high MFs (in a concentration of eight times the MIC, MF reached 7.0×10 -2 and 1.1×10 -3 for Ac-680 and Ac-Cl, respectively). These same isolates showed a bactericidal effect with no regrowth at 24 h by our time-kill assay, suggesting that the VAN-PMB combination may have the potential to block the hypermutation of these isolates. One isolate (Ac-576) showed confluent growth when 10 10 cells were applied to the plate, but no colony was recovered in the twofold serial dilution. Similar observations were recorded in another study of mutant estimation, which found a sharp decrease in the growth of some isolates within a range of only one dilution [27] .
Yang et al. [18] and O' Hara et al. [19] conducted synergy studies using a Galleria mellonella model and reported that the COL-VAN combination increased the percentage of G. mellonella survival at 96-120 h after infection in comparison to monotherapy with COL. Although COL-methanesulfonate is normally administered to treat human infections, the authors used pure COL in their study because G. mellonella does not have the enzymes needed to convert COL-methanesulfonate. Therefore, considering the pharmacokinetic differences between PMB and COL, we believe that the data obtained in the present study using PMB could be extrapolated more directly to humans with systemic infections. Studies using COL may not be as reliable for these infections because only a small fraction of the COL-methanesulfonate is converted to COL systemically, whereas about 70 % of this prodrug is excreted in the urine in humans with normal renal function [8, 28] .
To the best of our knowledge, only one study has evaluated the increased risk of renal toxicity caused by the PMB-VAN combination [29] , and the data available in the literature on the COL-VAN combination are contradictory. GarnachoMontero et al. [30] reported that nephrotoxicity was significantly higher in patients treated with COL-VAN, compared to patients treated with COL alone. Kalin et al. [31] found no differences in kidney injury rates in patients using antimicrobials concomitantly or in monotherapy. PMB appears to be less nephrotoxic than COL-methanesulfonate in patients [32] , indicating that the PMB-VAN combination may cause less kidney injury than the COL-VAN combination.
Researchers have suggested that the mechanism of synergism observed in the VAN plus polymyxins is based on polymyxins disrupting the outer membrane of GN bacilli, facilitating the penetration of VAN [7, 18, 19] . We also suggest that hydroxyl radicals produced by using polymyxins would interact synergistically with VAN, resulting in cell death. In bacteria, polymyxins induce the production of hydroxyl radicals, which damage DNA [33] , and these agents that damage DNA may show strong synergy with VAN [34] .
The present in vitro study on the antimicrobial synergism of the PMB-VAN combination has some inherent limitations, as in vitro results do not always coincide with in vivo results. However, our data clearly showed the potential of the PMB-VAN combination, especially against PMB-resistant isolates (MIC ≥4 µg ml -1 ). The small number of A. baumannii isolates used to evaluate the synergistic effect of the PMB-VAN combination can also be criticized. Nonetheless, the six different bacterial clusters tested can be considered a broad representation of this pathogen.
In conclusion, based on the in vitro data obtained in the present study, the PMB-VAN combination clearly showed a synergistic effect, especially against PMB-resistant A. baumannii. However, before this combination can be recommended for general clinical application, with no risk of toxicity, extensive animal studies and randomized clinical trials are required to identify the lowest practicable doses based on the pharmacokinetics and pharmacodynamics of these drugs.
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